- Home
- LDTC vs CDT Comparison
LDTC vs CDT Comparison
Compare LDTC & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDTC
- CDT
- Stock Information
- Founded
- LDTC 2007
- CDT 2019
- Country
- LDTC Canada
- CDT United States
- Employees
- LDTC N/A
- CDT N/A
- Industry
- LDTC Blank Checks
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- LDTC Finance
- CDT Health Care
- Exchange
- LDTC Nasdaq
- CDT Nasdaq
- Market Cap
- LDTC 10.6M
- CDT 10.2M
- IPO Year
- LDTC N/A
- CDT N/A
- Fundamental
- Price
- LDTC $1.01
- CDT $0.07
- Analyst Decision
- LDTC Buy
- CDT
- Analyst Count
- LDTC 3
- CDT 0
- Target Price
- LDTC $3.00
- CDT N/A
- AVG Volume (30 Days)
- LDTC 21.8M
- CDT 43.7M
- Earning Date
- LDTC 12-18-2024
- CDT 02-14-2025
- Dividend Yield
- LDTC N/A
- CDT N/A
- EPS Growth
- LDTC N/A
- CDT N/A
- EPS
- LDTC N/A
- CDT N/A
- Revenue
- LDTC $353,686.00
- CDT N/A
- Revenue This Year
- LDTC N/A
- CDT N/A
- Revenue Next Year
- LDTC $9.55
- CDT N/A
- P/E Ratio
- LDTC N/A
- CDT N/A
- Revenue Growth
- LDTC 141.86
- CDT N/A
- 52 Week Low
- LDTC $0.22
- CDT $0.07
- 52 Week High
- LDTC $9.99
- CDT $6.10
- Technical
- Relative Strength Index (RSI)
- LDTC 53.75
- CDT 37.75
- Support Level
- LDTC $1.05
- CDT $0.08
- Resistance Level
- LDTC $2.05
- CDT $0.09
- Average True Range (ATR)
- LDTC 0.34
- CDT 0.01
- MACD
- LDTC 0.06
- CDT -0.00
- Stochastic Oscillator
- LDTC 30.12
- CDT 7.61
About LDTC LeddarTech Holdings Inc.
LeddarTech Holdings Inc is a company that develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving (AD) applications. Its automotive-grade software applies AI and computer vision algorithms to generate accurate 3D models of the environment, allowing for decision-making and safer navigation.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.